Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatme...

Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate

CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN ) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

SUNRISE, Fla., July 28 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the US FDA cleared a p...

Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)

Partnership will offer expanded access to choice, quality and cost-efficiency for patients and payers WICHITA, Kan. and AVENTURA, Fla., June 24 /PRNewswire/ -- Galichia Heart Hospital and Mobile Surgery International (MSI) have reached an agreement for Galichia to host MSI-coordinated, highly...

Scientists identify gene vital to early embryonic cells forming a normal heart and skull

New research from Cincinnati Children's Hospital Medical Center highlights the critical role a certain gene and its protein play during early embryonic development on formation of a normal heart and skull. In a study posted online June 15 by the Proceedings of the National Academy of Sciences ...

Berlin Heart Inc. Receives FDA Orphan Product Development Grant

THE WOODLANDS, Texas, June 17 /PRNewswire/ -- Berlin Heart Inc. today announced it has been awarded an Orphan Product Development Grant by the FDA, to support the ongoing Investigational Device Exemption (IDE) study of the EXCOR(R) Pediatric Ventricular Assist Device (VAD). Dr. Christopher Alm...

PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice

Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced today that positive preclinical results of its novel cardioprotective agent, GP531, were reported in a poster...

500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device

BERLIN, May 28 /PRNewswire/ -- The 500th patient was supported with the Berlin Heart EXCOR(R) Pediatric Ventricular Assist Device (also known as the "Berlin Heart") since the first implantation of the device in 1990. The patient, an 11-month-old girl, received the device at the Children's Memo...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

Universal Definition of Myocardial Infarction provided jointly by leading international cardiology societies TOKYO and INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Investigators from the Phase III TRITON-TIMI 38 study applied the new classification system for the Universal Definition of Myo...

Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, received notification from the U.S. Food and Drug Administration (FDA) that the agency has released the Company's CD-N...

Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions

NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and news announcements at the 30th Annual Scientific Sessions of the Heart Rhythm Society, which run from May 13 to 16 in Boston. Highlights of t...

deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes

REYKJAVIK, Iceland, and ALAMEDA, California, April 23 /PRNewswire-FirstCall/ -- deCODE genetics (NASDAQ: DCGN ) and Celera Corporation (NASDAQ: CRA ) today announced the signing of agreements under which deCODE has granted Celera non-exclusive worldwide licenses to deCODE's genetic markers f...

Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy

European Trials Commencing for Injectable Biopolymer to Repair Weakened Heart Wall LAGUNA HILLS, Calif., April 14 /PRNewswire/ -- Symphony Medical, Inc., a developer of novel biopolymer therapies to cardiac abnormalities, announced today that its patented flagship technology, Algisyl-LVR(R), ...

The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of SERCA2a Enzyme Replacement Using Gene Transfer SAN DIEGO, April 8 /PRNewswire/ -- Celladon Corporation today announced the publication of results ...

Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial

Central Texas man receives groundbreaking therapy days after heart attack AUSTIN, Texas, March 31 /PRNewswire/ -- On March 30, the Heart Hospital of Austin treated the first patient in the world enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of a...

Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session

- First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion - ORLANDO, Fla., March 30 /PRNewswire/ -- Amorcyte, Inc. (Amorcyte) today announced data from its Phase I clinical trial of AMR-001, the company's lead product for the treatment of damaged heart muscle fol...

New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando

Results of five clinical studies evaluating the predictive value of VENDYS®, the new FDA-approved cardiovascular test, will be presented at the 2009 Annual Scientific Sessions of the American College of Cardiology in Orlando, Florida. The studies, amazingly, show that a simple, inexpensive te...

Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure

SAN FRANCISCO, March 27 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a leading company in the development of novel therapeutics for heart failure patients, announced today that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile ...

Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test

ApoAI and apoB/apoAI ratio now available with VAP Cholesterol Test at no additional cost BIRMINGHAM, Ala., March 10 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced the addition of apolipoprotein A (apoAI) to its VAP(R) Cholesterol Test. The VAP (Vertical Auto Pr...

VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs

Advanced cholesterol test helps usher in new era of specialized test for cardiac risk assessment BIRMINGHAM, Ala., Feb. 19 /PRNewswire/ -- For the Pittsburgh Steelers, adding a heart-healthy supplement to their diet may have given them the boost to win Super Bowl XLIII. That's according t...

KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure

Results of first clinical trial indicate pre-converted form of Coenzyme Q10 positively impacted heart function in critically ill subjects HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clinical trial evaluating ubiquinol's effects on late-stage congestive heart failure showed that th...

VAP Cholesterol Test Helps In Search For New Heart Disease Drugs

Peer-reviewed journal, Science, reports that advanced cholesterol test aids in identifying connection between improved lipid profile and heart protection BIRMINGHAM, Ala., Feb. 16 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers h...

Cordex Pharma Forms Heart Failure Medical Advisory Board

Dr. Joshua Hare to Chair the Board LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of ...

Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack

REYKJAVIK, Iceland, February 9 /PRNewswire-FirstCall/ -- In a paper published today, scientists at deCODE genetics (Nasdaq: DCGN ) and academic colleagues from four continents present a novel insight into the connection between inflammation and heart disease. Through a genome-wide search in s...

BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women

Discounted Cholesterol Test Kits Help Women Detect Serious Health Problems While Making Charitable Donations SANTA BARBARA, Calif., Feb. 6 /PRNewswire/ -- Yes, the truth sometimes hurts. But when it comes to women's health, it's better to face the facts: one in four women in the United States...

Traditional Risk Factors Often Miss Heart Disease Warning Signs

VAP(R) Cholesterol Test helps physicians identify emerging risk factors better than standard cholesterol test and traditional risk factors, study shows BIRMINGHAM, Ala., Jan. 30 /PRNewswire/ -- Traditional risk factors such as age, standard cholesterol levels and blood pressure do a poor jo...

New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns

Study Published in British Medical Journal Indicates Masimo SET May Also Reduce the Need for Pre-Operative Neonatal Intensive Care and Prevent Long-term Neurological Morbidity IRVINE, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and...

Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced that it will focus resources on the development of its natriuretic peptide franchise, including CD-NP which is in Phase II development for acute heart failure, and CU-NP which is a pre-clini...

Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure

SAN FRANCISCO, Dec. 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced preliminary data from its recently completed multi-center, open-label, ascending-dose Phase 1b clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients with heart failure. R...

Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President

ANN ARBOR, Mich., Nov. 24 /PRNewswire/ -- Terumo Heart, Inc. is pleased to announce the appointment of William Pinon to the position of Chief Executive Officer (C.E.O.) and President, effective immediately. "With its innovative mag-lev technology, Terumo Heart is positioned for a strong leadership...

CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate

LAS VEGAS, Nov. 13 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) (the "Company") has entered into its first clinical development agreement for its Coronary Heart Disease drug candidate with Cardio Neo-Genesis, LP ("CNG"). The agreement, dated Novembe...

Arizona Heart Innovative Technologies Licenses New Endovascular Device

PHOENIX, Nov. 12 /PRNewswire/ -- Arizona Heart Innovative Technologies, LLC (AHIT) announced the license of a new medical device for endovascular use to a publicly traded medical device company. "This is the second AHIT-developed product that we have licensed in the past ten months. We continu...

Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy

REYKJAVIK, Iceland, Nov. 11 /PRNewswire-FirstCall/ -- In a presentation today at the American Heart Association Scientific Sessions 2008, clinicians and researchers from Baylor College of Medicine have presented data from the Atherosclerosis Risk in Communities (ARIC) study, demonstrating that...

Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease

HAYWARD, Calif., Nov. 11 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead product, varespladib (A-002) at the American Heart Association (AHA) Annual Conference in New Orleans, Lou...

BSP Signs Agreement With CMP Trading for Distribution of HyperQ(TM) Stress System, for Early Detection of Ischemic Heart Disease, in South Korea

CMP Will Purchase at Least 227 HyperQ(TM) Systems During the Term of the Agreement TEL AVIV, Israel, November 10 /PRNewswire-FirstCall/ -- BSP (Biological Signal Processing Ltd.) ( http://www.bsp.co.il/ ), an Israeli company that develops and markets innovative sy...

Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure

SAN MATEO‚ Calif.‚ Nov. 10 /PRNewswire/ -- Corthera Inc. today announced that an interim analysis of top-line data from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, international study, showed favorable efficacy and safety for relaxin, the compan...

Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association

New Data Presented at the Meeting Report the Use of Haptoglobin Typing to Predict Cardiovascular Risk, and Benefit From Tight Glycemic Control in Diabetics MONTVALE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI ) today announced at the Annual Scientific Ses...

Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today

NEW ORLEANS and LOS ANGELES, November 10 /PRNewswire/ -- - Current Treatment Fails to Abolish Majority of Vascular Risk - Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards of Care in Millions of Pat...

Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008

Atherotech to add new apoA1 measurement and apoB:apoA1 ratio to its comprehensive cholesterol test, further identifying patients at risk of heart disease BIRMINGHAM, Ala., Nov. 6 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it w...

Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008

SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data from a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented next week at a satellite symposium at the American Heart Association's (AHA) Scientific S...